Health
Virus drug benefit only marginal: study – Shepparton News
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.The 600-patient analysis, published on Friday by the Journal of the American Medical …
-
Noosa News24 hours agoMeasles alert issued across popular south-east attractions
-
General24 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
Noosa News22 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
General18 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts